Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Inv. presentation
|
Y-mAbs Therapeutics, Inc. (YMAB)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/10/2023 |
8-K
| Quarterly results |
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/26/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/23/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
05/08/2023 |
8-K
| Quarterly results |
05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/18/2023 |
8-K
| Quarterly results |
04/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
04/03/2023 |
SC 13G
| ACORN BIOVENTURES, L.P. reports a 5.3% stake in Y-mAbs Therapeutics, Inc. |
03/13/2023 |
8-K
| Other Events Interactive Data |
02/14/2023 |
SC 13G/A
| HBM Healthcare Investments Ltd. reports a 8.7% stake in Y-mAbs Therapeutics, Inc. |
02/14/2023 |
SC 13G
| WG Biotech ApS reports a 9.8% stake in Y-mAbs Therapeutics, Inc. |
02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5.2% stake in Y-mAbs Therapeutics Inc. |
02/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/04/2023 |
8-K
| Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Fi... |
12/21/2022 |
8-K
| Quarterly results |
12/16/2022 |
8-K
| Quarterly results |
12/14/2022 |
8-K
| Quarterly results |
12/08/2022 |
8-K
| Quarterly results |
12/01/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/07/2022 |
8-K
| Quarterly results
Docs:
|
"Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets September 30, December 31, 2022 2021 ASSETS CURRENT ASSETS Cash and cash equivalents $ 114,526 $ 181,564 Accounts receivable, net 9,251 7,712 Inventories 6,242 5,512 Other current assets 3,225 7,473 Total current assets 133,244 202,261 Property and equipment, net 1,372 1,847 Operating lease right-of-use assets 2,169 3,842 Intangible assets, net 1,530 1,663 Other assets 5,600 3,170 TOTAL ASSETS $ 143,915 $ 212,783 LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Accounts payable $ 13,723 $ 13,552 Accrued liabilities 17,092 12,540 Operating lease liabilities, current portion 1,200 1,783 Total current liabilities 32,015 27,875 Accrued milestone payments 2,250 2,100 Operating lease liabilities, long-term portion 1,019 1,851 Other liabiliti..." |
|
10/28/2022 |
8-K
| Quarterly results |
10/03/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
09/26/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
09/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
09/02/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
08/30/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|
|
|